Skip to main content

Table 1 Clinical characteristics of the patients with NAFLD and control subjects

From: Association of the rs738409 polymorphism in PNPLA3 with liver damage and the development of nonalcoholic fatty liver disease

 

NAFLD (n = 253)

Control (n = 578)

Pvalue

Men/women

122/131

182/396

<0.0001*

Age (year)

51.7 ± 15.0

(38.0; 52.5; 64.0)

47.2 ± 14.8

(34.0; 49.0; 57.0)

<0.0001

BMI (kg/m2)

27.7 ± 5.3

(24.4; 27.3; 29.8)

21.3 ± 2.2

(19.8; 21.4; 23.1)

<0.0001

FBS (mg/dL)

117.1 ± 34.6

(99.0; 108.0; 124.0)

90.9 ± 7.7

(85.0; 90.5; 96.0)

<0.0001

HbA1c (%)

5.9 ± 1.2

(5.1; 5.5; 6.3)

5.0 ± 0.4

(4.8; 5.0; 5.3)

<0.0001

Total cholesterol (mg/dL)

212.3 ± 37.9

(183.0; 212.0; 237.0)

202.3 ± 34.4

(177.0; 202.0; 223.0)

0.0014

Triglycerides (mg/dL)

169.9 ± 97.7

(112.0; 148.0; 205.0)

75.7 ± 28.6

(53.0; 70.0; 95.0)

<0.0001

HDL cholesterol (mg/dL)

52.5 ± 17.4

(42.0; 49.0; 58.0)

67.4 ± 14.0

(57.0; 66.0; 75.8)

<0.0001

Systolic blood pressure (mm Hg)

126.7 ± 15.5

(114.0; 125.0; 138.0)

111.1 ± 10.2

(104.0; 112.0; 120.0)

<0.0001

Diastolic blood pressure (mm Hg)

77.5 ± 11.4

(70.0; 78.0; 86.0)

69.4 ± 7.5

(64.0; 70.0; 75.8)

<0.0001

AST (IU/L)

48.6 ± 29.7

(27.0; 37.0; 64.0)

19.9 ± 6.4

(15.0; 18.0; 23.0)

<0.0001

ALT (IU/L)

76.2 ± 50.7

(37.8; 61.0; 93.3)

15.6 ± 6.4

(11.0; 14.0; 19.0)

<0.0001

  1. Data are represented as the mean ± SD (25th, 50th, and 75th percentile). P values were obtained by comparing the quantitative phenotype between 2 groups (Mann-Whitney U test). *Men/women ratio was analyzed by Fisher's exact test. AST, aspartate transaminase; ALT, alanine transaminase; BMI, body mass index; FBS, fasting blood sugar; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; NAFLD, nonalcoholic fatty liver disease.